Circle’s existing operations continued to progress in H116, with revenues ahead 6% year-on-year in H116 and both business units again generating positive EBITDA. The group EBITDA loss after central costs declined further and we estimate positive EBITDA for 2018. Management is focused on further diversifying the group offering and building the scale required to generate attractive overall returns. Already preferred bidder for a new musculoskeletal (MSK) contract in Greenwich, Circle seek
09 Dec 2016
Healthy options
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy options
- Published:
09 Dec 2016 -
Author:
Andrew Mitchell -
Pages:
16
Circle’s existing operations continued to progress in H116, with revenues ahead 6% year-on-year in H116 and both business units again generating positive EBITDA. The group EBITDA loss after central costs declined further and we estimate positive EBITDA for 2018. Management is focused on further diversifying the group offering and building the scale required to generate attractive overall returns. Already preferred bidder for a new musculoskeletal (MSK) contract in Greenwich, Circle seek